Research progress of hypofractionated whole breast irradiation after breast conserving surgery

doi:10.3760/cma.j.issn.1673-422X.2018.09.013

Abstract

Abstract: Hypofractionated radiotherapy after breast conserving surgery has become a new standard treatment of early breast cancer. Clinical researches show that α/β value of breast cancer is lower than that of other tumors, and the breast cancer is more suitable for hypofractionated radiotherapy. Hypofractionated radiotherapy has good economic benefits, and longterm followup results from a number of classical randomized controlled studies have shown that hypofractionated whole breast irradiation is effective and safe. With the extensive application of hypofractionated irradiation, this technology has been gradually extended to regional nodal irradiation, postmastectomy radiotherapy and breast ductal carcinoma in situ.

Key words: Breast neoplasms, Radiotherapy, Treatment effect, Breast conserving surgery, Sideeffects

Zheng Linjing, Dong Yinping, Hu Bing, Xia Chongsheng, Li Baosheng, Huang Wei. Research progress of hypofractionated whole breast irradiation after breast conserving surgery[J]. Journal of International Oncology, 2018, 45(8): 570-573.

References

［1］ Qi XS, White J, Li XA. Is α/β for breast cancer really low?［J］. Radiother Oncol, 2011, 100(2): 282288. DOI: 10.1016/j.radonc.2011.01.010. ［2］ Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: longterm results of a randomised trial［J］. Radiother Oncol, 2005, 75(1): 917. DOI: 10.1016/j.radonc.2005.01.005. ［3］ Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with earlystage breast cancer after local tumour excision: longterm results of a randomised trial［J］. Lancet Oncol, 2006, 7(6): 467471. DOI: 10.1016/S14702045(06)706994. ［4］ START Trialists′ Group, Bentzen SM, Agrawal RK, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial［J］. Lancet Oncol, 2008, 9(4): 331341. DOI: 10.1016/S14702045(08)700779. ［5］ Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10year followup results of two randomised controlled trials［J］. Lancet Oncol, 2013, 14(11): 10861094. DOI: 10.1016/S14702045(13)703863. ［6］ Yarnold J. Hypofractionation, rationale, current status and futuredirections［R］. ASTRO′s 56th Annual Meeting. San Francisco, CA: Fairfax, VA. 2014: 1417. ［7］ Versmessen H, VinhHung V, Van Parijs H, et al. Healthrelated quality of life in survivors of stage ⅠⅡ breast cancer: randomized trial of postoperative conventional radiotherapy and hypofractionated tomotherapy［J］. BMC Cancer, 2012, 12: 495. DOI: 10.1186/1471240712495. ［8］ Greenup RA, Camp MS, Taghian AG, et al. Cost comparison of radiation treatment options after lumpectomy for breast cancer［J］. Ann Surg Oncol, 2012, 19(10): 3275 3281. DOI: 10.1245/s1043401225465. ［9］ Ciafre AC, Torices JM, Jordá E, et al. EP1143 Hypofractionated vs conventionally fractionated breast radiotherapy: Economic consequences［R］. ESTRO 36. Ireland: Elsevier Ltd. 2017: S622. ［10］ Niska JR, Keole SR, Pockaj BA, et al. Choosing wisely after publication of level Ⅰ evidence in breast cancer radiotherapy［J］. Breast Cancer (Dove Med Press): 2018, 10: 3137. DOI: 10.2147/BCTT.S153117. ［11］ Whelan T, MacKenzie R, Julian J, et al. Randomized tiral of breast irradiation schedules after lumpectomy for women with lymph nodenegative breast cancer［J］. J Natl Cancer Inst, 2002, 94(15): 11431150. DOI: 10.1093/jnci/94.15.1143. ［12］ Whelan TJ, Pignol JP, Levine MN, et al. Longterm results of hypofractionated radiation therapy for breast cancer［J］. N Engl J Med, 2010, 362(6): 513520. DOI: 10.1056/NEJMoa0906260. ［13］ START Trialists′ Group, Bentzen SM, Agrawal RK, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised thail［J］. Lancet, 2008, 371(9618): 10981107. DOI: 10.1016/S01406736(08)603487. ［14］ Swanick CW, Lei X, Shaitelman SF, et al. Longitudinal analysis of patientreported outcomes and cosmesis in arandomized trial of conventionally fractionated versus hypofractionated wholebreast irradiation［J］. Cancer, 2016, 122(18): 28862894. DOI: 10.1002/cncr.30121. ［15］ Early Breast Cancer Trialists′ Collaborative Group (EBCTCG), Correa C, McGale P, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast［J］. J Natl Cancer Inst Monogr, 2010, 2010(41): 162177. DOI: 10.1093/jncimonographs/lgq039. ［16］ Lalani N, Paszat L, Sutradhar R, et al. Longterm outcomes of hypofractionation versus conventional radiation therapy after breastconserving surgery for ductal carcinoma in situ of the breast［J］. Int J Radiat Oncol Biol Phys, 2014, 90(5): 10171024. DOI: 10.1016/j.ijrobp.2014.07.026. ［17］ Rakovitch E, Narod SA, NofechMoses S, et al. Impact of boost radiation in the treatment of ductal carcinoma in situ: a populationbased analysis［J］. Int J Radiat Oncol Biol Phys, 2013, 86(3): 491497. DOI: 10.1016/j.ijrobp.2013.02.031. ［18］ Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with highrisk breast cancer receiving adjuvant chemotherapy: 20year results of the British Columbia randomized trial［J］. J Natl Cancer Inst, 2005, 97(2): 116126. DOI: 10.1093/jnci/djh297. ［19］ Danish Breast Cancer Cooperative Group, Nielsen HM, Overgaard M, et al. Study of failure pattern among highrisk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: longterm results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomised studies［J］. J Clin Oncol, 2006, 24(15): 22682275. DOI: 10.1200 / JCO.2005.02.8738. ［20］ Galecki J, HicerGrzenkowicz J, GrudzieńKowalska M, et al. Radiationinduced brachial plexopathy and hypofractionated regimens in adjuvant irradiation of patients with breast cancer—a review［J］. Acta Oncol, 2006, 45(3): 280284. DOI: 10.1080/02841860500371907. ［21］ Badiyan SN, Shah C, Arthur D, et al. Hypofractionated regional nodal irradiation for breast cancer: examining the data and potential for future studies［J］. Radiother Oncol, 2014, 110(1): 3944. DOI: 10.1016/j.radonc. 2013.12.006. ［22］ Coles CE, Griffin CL, Kirby AM, et al. Partialbreast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5year results from a multicentre, randomised, controlled, phase 3, noninferiority trial［J］. Lancet, 2017, 390(10099): 10481060. DOI: 10.1016/S01406736(17)311455. ［23］ Olivotto IA, Whelan TJ, Parpia S. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using threedimensional conformal external beam radiation therapy［J］. J Clin Oncol, 2013, 31(32): 40384045. DOI: 10.1200/JCO.2013.50.5511. ［24］ Ashworth A, Kong W, Whelan T, et al. A populationbased study of the fractionation of postlumpectomy breast radiation therapy［J］. Int J Radiat Oncol Biol Phys, 2013, 86(1): 5157. DOI: 10.1016/j.ijrobp.2012.12.015. ［25］ Peterson D, Truong PT, Parpia S, et al. Predictors of adverse cosmetic outcome in the RAPID Trial: an exploratory analysis［J］. Int J Radiat Oncol Biol Phys, 2015, 91(5): 968976. DOI: 10.1016/j.ijrobp.2014.12.040. ［26］ Smith BD, Bentzen SM, Correa CR, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidencebased guideline［J］. Int J Radiat Oncol Biol Phys, 2011, 81(1): 5968. DOI: 10.1016/j.ijrobp.2010.04.042.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[6]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[7]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[8]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[9]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[10]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[11]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[12]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[13]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[14]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[15]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.